NCT04479202View on ClinicalTrials.gov

The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19

PHASE4CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

February 8, 2020

Primary Completion Date

April 18, 2020

Study Completion Date

April 23, 2020

Conditions
BerberineCOVID-19
Interventions
DRUG

Berberine

Patients in the intervention group received berberine daily, regardless of gastrointestinal symptoms.If the patient has a serious drug-related adverse event, the drug will be discontinued and the patient will be excluded from the study.

DRUG

Montmorrillonite

Patients in the control group were routinely not given special treatment.However, if the patient has diarrhea symptoms, montmorillonite powder should be given orally.

Trial Locations (1)

210008

Nanjing Drum Tower Hospital, Nanjing

All Listed Sponsors
lead

Chinese Medical Association

NETWORK

NCT04479202 - The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19 | Biotech Hunter | Biotech Hunter